-
Mashup Score: 27Rally Foundation Awards $5M for a Record Number of Grants to 74 Childhood Cancer Researchers - 17 day(s) ago
This year, 51 researchers across 31 institutions worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research.
Source: rallyfoundation.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Study successfully mimics complex neuroblastoma vasculature on a chip to explore treatments - 22 day(s) ago
Neuroblastoma, one of the most common childhood cancers, is classified as a developmental cancer because it arises prenatally during the formation of organs and tissues. It originates from cancer cells …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Study successfully mimics complex #neuroblastoma vasculature on a chip to explore treatments https://t.co/vQYtanMZbY
-
-
Mashup Score: 25Researchers discover a signaling molecule in neuroblastoma immunosuppression and aggressiveness - 1 month(s) ago
The MYCN oncoprotein (proteins related to the growth of cancer cells) plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially …
Source: medicalxpress.comCategories: General Medicine News, General NewsTweet-
Researchers discover a signaling molecule in #neuroblastoma immunosuppression and aggressiveness @BUMedicine @ScienceAdvances https://t.co/3r5W8nIIKt
-
-
Mashup Score: 14
Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients’ T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn’t work …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Combining CAR-T cells and inhibitor drugs for high-risk #neuroblastoma @bostonchildrens https://t.co/QnxlHiey3D
-
-
Mashup Score: 6
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B). MATERIALS AND METHODS Patients age 1-21 years with RR-HRNB with adequate organ function and performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) with or without B. The primary end point was best overall response (complete or partial) rate (ORR) during the first six courses, by RECIST or International Neuroblastoma Response Criteria for patients with measurable or evaluable disease, respectively. Safety, progression-free survival (PFS), and overall survival (OS) time were secondary end points. RESULTS One hundred sixty patients with RR-HRNB were included. For B random assignment (n = 160), the ORR was 26% (95% CI, 17 to
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Promising activity seen for bevacizumab, irinotecan and temozolomide in #neuroblastoma: https://t.co/KJw5krxerI @CCBD_VHResearch
-
-
Mashup Score: 3NCCN Guidelines Give Framework for Childhood Neuroblastoma Treatment - 2 month(s) ago
New guidelines provide a framework for pediatric neuroblastoma treatment — as well as conversations families should have with their oncology teams.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
The @NCCN have new guidelines that provide framework for #neuroblastoma treatment in children. Read to Learn More: https://t.co/8tkFKtvyJ9
-
-
Mashup Score: 1
Much of our cutting-edge work is only possible because of the help we receive from our supporters, including our wonderful family charity partners. Dr Sally George, who leads our Developmental Oncology group at the ICR, explains why these partnerships are so important.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our family charity partners have a key role in driving progress in #CancerResearch. Dr Sally George, leader of our Developmental Oncology Team, shares how Siobhan’s Superstar Legacy supports our #Neuroblastoma work to give hope to #ChildrenWithCancer⬇️ https://t.co/6dy7NDGeQd
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers conducted a study showing #lorlatinib is safe and effective in treating high-risk #neuroblastoma in children, adolescents, and adults with relapsed or refractory ALK-mutated or ALK-amplified neuroblastoma. @WinshipAtEmory @ChildrensPhila https://t.co/GrLecz21tH https://t.co/4KRLjDtNMw
-
-
Mashup Score: 4CTG Labs - NCBI - 8 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Proud @WiscPediatrics @UWCarbone @UWHealth to be the only US site collaborating with Dr Gray on this innovative trial combining MIBG, anti-PD1 and anti-GD2 #neuroblastoma 1st transatlantic trial #childhoodcancerawarenessmonth https://t.co/MDxJN4tEuJ https://t.co/bZkkqYK2c1
-
-
Mashup Score: 1Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation - 8 month(s) ago
Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the most recent issue— Alpha-1 Adrenergic Antagonists Sensitize #Neuroblastoma to Therapeutic Differentiation, by Broso et al. https://t.co/iC37x19XkS @UniTrento https://t.co/Mb5a1jrJy2
-
Announced today (not an April fools joke)! So thankful to the @RallyFoundation for their support for @ADurbinLab postdocs @ShendyNoha and Ian Delahunty! Both working on targeting #neuroblastoma through innovative new ways (though Noha is on hiatus). https://t.co/IuUFglsDNB